NPCE Stock Overview
Operates as a medical device company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NeuroPace, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.35 |
| 52 Week High | US$18.15 |
| 52 Week Low | US$5.45 |
| Beta | 2.06 |
| 1 Month Change | 11.27% |
| 3 Month Change | 69.91% |
| 1 Year Change | 13.50% |
| 3 Year Change | 22.57% |
| 5 Year Change | n/a |
| Change since IPO | -54.53% |
Recent News & Updates
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
Dec 04
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
Nov 14Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Nov 07Recent updates
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
Dec 04Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
Nov 14Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Nov 07NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
Aug 03Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Apr 12NeuroPace: Picking Up The Pace
Feb 25Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Jan 22NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
Apr 17NeuroPace announces U.S. distribution agreement with DIXI Medical
Aug 11NeuroPace EPS misses by $32.45, beats on revenue; issues guidance
Jun 03Shareholder Returns
| NPCE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.9% | 2.3% | 2.8% |
| 1Y | 13.5% | 10.1% | 24.5% |
Return vs Industry: NPCE exceeded the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: NPCE underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| NPCE volatility | |
|---|---|
| NPCE Average Weekly Movement | 12.2% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NPCE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NPCE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 184 | Joel Becker | www.neuropace.com |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
NeuroPace, Inc. Fundamentals Summary
| NPCE fundamental statistics | |
|---|---|
| Market cap | US$332.51m |
| Earnings (TTM) | -US$28.09m |
| Revenue (TTM) | US$76.45m |
4.4x
P/S Ratio-12.1x
P/E RatioIs NPCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPCE income statement (TTM) | |
|---|---|
| Revenue | US$76.45m |
| Cost of Revenue | US$20.01m |
| Gross Profit | US$56.44m |
| Other Expenses | US$84.53m |
| Earnings | -US$28.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 73.83% |
| Net Profit Margin | -36.74% |
| Debt/Equity Ratio | 603.3% |
How did NPCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:23 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NeuroPace, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Robert Marcus | J.P. Morgan |